GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellect Biotechnology Ltd (NAS:APOP) » Definitions » EV-to-EBIT

Cellect Biotechnology (Cellect Biotechnology) EV-to-EBIT : -5.81 (As of Apr. 26, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cellect Biotechnology EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cellect Biotechnology's Enterprise Value is $10.27 Mil. Cellect Biotechnology's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-1.77 Mil. Therefore, Cellect Biotechnology's EV-to-EBIT for today is -5.81.

The historical rank and industry rank for Cellect Biotechnology's EV-to-EBIT or its related term are showing as below:

APOP' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.12   Med: 0   Max: 0
Current: -28.19

APOP's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 8.41 vs APOP: -28.19

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cellect Biotechnology's Enterprise Value for the quarter that ended in Jun. 2021 was $0.00 Mil. Cellect Biotechnology's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-1.77 Mil. Cellect Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was %.


Cellect Biotechnology EV-to-EBIT Historical Data

The historical data trend for Cellect Biotechnology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellect Biotechnology EV-to-EBIT Chart

Cellect Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-EBIT
Get a 7-Day Free Trial -3.14 -7.06 -9.89 - -

Cellect Biotechnology Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Jun21
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cellect Biotechnology's EV-to-EBIT

For the Biotechnology subindustry, Cellect Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellect Biotechnology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellect Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cellect Biotechnology's EV-to-EBIT falls into.



Cellect Biotechnology EV-to-EBIT Calculation

Cellect Biotechnology's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=10.267/-1.767
=-5.81

Cellect Biotechnology's current Enterprise Value is $10.27 Mil.
Cellect Biotechnology's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellect Biotechnology  (NAS:APOP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cellect Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2021 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2021 ) =EBIT / Enterprise Value (Q: Jun. 2021 )
=-1.767/0
= %

Cellect Biotechnology's Enterprise Value for the quarter that ended in Jun. 2021 was $0.00 Mil.
Cellect Biotechnology's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellect Biotechnology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cellect Biotechnology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellect Biotechnology (Cellect Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
23 Hata’as Street, Kfar Saba, ISR, 44425
Cellect Biotechnology Ltd is a biotechnology company that has developed a novel technology platform known as ApoGraft that functionally selects cells in order to improve the safety and efficacy of regenerative medicine and cell therapies. The company is developing its first product based on its ApoGraft technology platform, the ApoTainer kit that utilizes FasL- apoptotic protein.

Cellect Biotechnology (Cellect Biotechnology) Headlines